English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Although it has been generally recognized that there are inconsistencies among  R egional  R eview  B oards in the assignment of points for model for end‐stage liver disease ( MELD )/pediatric end‐stage liver disease ( PELD ) exception patients with resulting considerable variation in appeal denial rates, data to actually prove this have been limited. We reviewed 6533  MELD / PELD  exception applications submitted between 2005 and 2008, calculated the variation in approval/denial rates, and followed these cases through mid‐2013 to assess the effects on patient outcomes. We found highly significant regional variations in denial rates for appeals by exception patients and in transplantation rates. The odds of transplant for patients whose appeals are approved is 2.45 times that of patients not approved; that this effect does not vary by region suggests that the variation in transplant rates is driven, at least in part, by the variation in appeal denial rates. Health deterioration or death accounts for more than two‐thirds of wait list removals among patients removed for reasons other than transplant. Our findings add to the weight of evidence that a national review board that uses current clinical expertise, peer review literature, and data to consistently assign priority could reduce regional inequities and move toward equitable allocation of organs and compliance with the  U nited  S tates  D epartment of  H ealth &  H uman  S ervices Final Rule.

clinical transplantation

U nited  N etwork for  O rgan  S haring regional variations in appeal denial rates with non‐standard Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exceptions: support for a national review board